Ottimo Pharma, a pioneering biotechnology company established in 2020 and co-founded by Medicxi and Jonny Finlay, has successfully raised $140 million in a recent funding round. This substantial injection of capital will significantly accelerate the company’s mission to develop groundbreaking cancer therapies specifically targeting solid tumors. Ottimo Pharma has garnered attention for its innovative lead program, Jankistomig, a revolutionary PD1-VEGFR2 bi-functional antibody that uniquely combines immune checkpoint inhibition with angiogenesis targeting in a single IgG therapy. This dual-pathway strategy is designed not only to enhance treatment efficacy but also to improve overall patient outcomes and alleviate the healthcare system's burden caused by cancer. Under the guidance of a world-class leadership team, including Chair and CEO David Epstein, CMO Mehdi Shahidi, and Vice-Chair James Sabry, Ottimo Pharma is poised for significant advancements in oncological care. The company is currently on track to file an Investigational New Drug (IND) application in late 2025, marking a critical milestone in the journey toward bringing Jankistomig to clinical trials. The recent funding will facilitate further research and development initiatives, paving the way for Ottimo Pharma to emerge as a leader in oncology solutions and reaffirm its commitment to transforming cancer treatment for patients worldwide.
Ottimo Pharma Secures $140 Million Funding for Revolutionary Cancer Therapies
Get the full Ottimo Pharma company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Maneva
Maneva AI revolutionizes manufacturing by offering a superhuman digital workforce tailored to the industry's unique needs. Our AI empowers factories to streamline operations, cut costs, and enhance productivity. Designed specifically for manufacturing, Maneva AI delivers a range of benefits, from reducing labor dependencies and enhancing quality assurance to eliminating downtime and preserving critical knowledge. Our seamless implementation ensures swift integration into existing workflows, guaranteeing remarkable returns on investment for manufacturers across America. Even tasks once deemed unautomatable are effortlessly handled by Maneva AI. Many challenges facing manufacturing companies, too intricate for costly automation projects, find solutions in our intelligent systems. Leveraging manufacturing-specific intelligence, Maneva AI consistently proves its efficacy, bringing companies closer to a future-proof state. Experience tangible, profitable, and tactical results with Maneva AI. Reach out now to discover how we can drive immediate impact for your business!
$27.0M Series a
today
Avon Health
Avon Health is powering next-gen healthcare. The Avon EMR is an AI-forward, infinitely customizable EMR to power next-gen care delivery practices, from solo primary clinics with 400 patients to virtual care companies with 100,000+ patients. Our customizable modules and APIs have enabled care delivery companies to customize their EMR and patient engagement platform in days, complete with functionality to treat patients in-person and virtually, bill insurance, automatically scribe medical notes using AI, automate workflows, and more.
$9.0M Seed
today
Wassist
The WhatsApp Agents Platform. Engage customers where they already chat. Hyper-personalized conversations with no invasive tracking, where you can checkout in your chat.
$1.1M Seed
today
Cordon Technologies
The world is in the middle of an AI and Robotics revolution. Cordon is bringing this to vineyards, reducing costs and allowing better, more sustainable farming. We are farmers ourselves. Cordon's solutions are reliable, robust, cost effective, and integrate seamlessly with your current machinery and day to day operations.
$1.3M Seed
today
Infinity Constellation
Infinity Constellation is the first AI services holding company, building category leaders designed to displace incumbents in the $9T+ professional services market. We give exceptional operators a 12-month head start—backed by capital, shared infrastructure, customers, back-office support, and shared equity—to launch outcome-driven businesses that redefine their industries.
$24.0M Series a
today